Table 4.

ADAM17 inhibitors and disease models tested. A disintegrin and metalloproteinase 17 (ADAM17) inhibitor drugs, their formulations and published research into treatment of various disease models in vitro and in vivo using mouse models or human clinical trials. scFv; small chain variable fragment, NSCLC; non-small cell lung cancer, HNSCC; head and neck squamous cell carcinoma, DLBCL; diffuse large B cell lymphoma, HCT; haematopoietic cell transplant.

Drug Name	Formulation	In Vitro Models	Mouse Models	Human Trials
INCB7839/ Aderbasib	Small molecule inhibitor	HER2 + breast cancer with trastuzumab [156]	High-grade glioma xenograft tumour model [157]	Phase I; paediatric glioma [150]
				Phase I/II; DLBCL in combination with rituximab, post autologous HCT [149]
			HER2+ breast cancer xenograft tumour model with trastuzumab [156]	Phase I; HER2+ metastatic breast cancer with trastuzumab [158]
BMS-561392/ DPC-333	Small molecule inhibitor	NSCLC [159]	Collagen-induced arthritis (CIA) model [161]	Phase II rheumatoid arthritis [161]
			Autoimmune hepatitis [162]
		Alzheimer’s [160]	Acute colitis [163]
			Alzheimer’s model [160]
			Spinal cord injury [164]
TMI-005/ Apratastat	Small molecule inhibitor	Polycystic kidney disease [165].	SARS-CoV-2 [166]	Phase II clinical trial for rheumatoid arthritis [152].
			NSCLC [167].
JTP-96193	Small molecule inhibitor		Type 2 diabetes & diabetic peripheral neuropathy [168].
D1(A12)	Human IgG antibody	HNSCC [169].	Ovarian xenograft tumour model [170].
		Triple negative breast cancer [171]
A9(B8)	Humanised mouse IgG2 antibody	NSCLC with erlotinib/ gefitinib [172].	Pancreatic cancer [173].
MEDI3622	Humanised mouse IgG1 antibody	Colorectal cancer [174].	Head and neck & colorectal xenograft tumour models [175]
		Ovarian cancer & Burkitt’s lymphoma [176]	Polymicrobial sepsis [177].